An FDA advisory panel narrowly recommended allowing compounding pharmacies to manufacture some unapproved peptides, setting up a pivotal next step for the agency’s final decision. Panelists supported epitalon while recommending against compounding emideltide, following Thursday’s discussion on additional peptides that would expand access.